Ramya Uppuluri

Ramya Uppuluri

Auto-generated profile, based on publicly available information

Ramya Uppuluri

Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation Apollo Hospitals Chennai Tamil Nadu India

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
RURamya Uppuluri
Ramya Uppuluri
MSMeena Sivasankaran
Meena Sivasankaran
SPShivani Patel
Shivani Patel
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
KRKesavan Melarcode Ramanan
Kesavan Melarcode Ramanan
RRRevathi Raj
Revathi Raj

1 July 2020 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
RURamya Uppuluri
Ramya Uppuluri
SPShivani Patel
Shivani Patel
NRNikila Ravichandran
Nikila Ravichandran
KRKesavan Melarcode Ramanan
Kesavan Melarcode Ramanan
RRRevathi Raj
Revathi Raj
Hematopoietic stem cell transplantation (HSCT) is the only curative option available for patients with thalassemia major in India with increasing access to alternate donor transplantation for patients with no matched family donor. We aimed to analyze the impact of family and alternate donor HSCT on morbidity and mortality post-HSCT. We conducted a retrospective study in the department between July 2007 and December 2018 where all children who underwent HSCT for thalassemia major were included. A total of 264 children were included with a median age of 6 years (male/female, 1.4:1). The graft source was matched related donor (MRD) (76%; parent 15%, sibling 85%) and matched unrelated donor (MUD) (22%). All children received a myeloablative conditioning regimen with treosulfan/thiotepa/fludarabine in 93% and busulfan/cyclophosphamide in 7%. The source of stem cells was peripheral blood in 61%, bone marrow in 38%, and umbilical cord blood in 3%. The incidence of bacteremia was 14% versus 25% in MRD versus MUD groups. There was a higher incidence of posterior reversible encephalopathy syndrome (PRES) in the MUD group (10% versus 3%). Engraftment occurred in 97% with a higher trend toward mixed chimerism in the MRD group (12% versus 2%). When indicated, whole-blood donor lymphocyte infusion was used to ensure complete chimerism in children in the MRD group. A statistically significant difference was found in the incidence of graft versus host disease (GVHD), both acute and chronic between the MUD versus MRD groups, 60% versus 20% and 41% versus 17%, respectively (P = .001). Similarly, immune cytopenia and cytomegalovirus reactivation were also significantly higher in the MUD group, 27% versus 1.4% and 25% versus 2%, respectively (P = .001). Thalassemia-free survival in our cohort was 96%, 94%, and 84% with a median follow-up of 65 months in the matched sibling donor, matched family donor, and MUD groups, respectively. Overall survival of 95% and 90% with a median follow-up of 65 months was noted in those who underwent transplantation less than and greater than 7 years of age, respectively. MUD transplantation for patients with thalassemia major involves specific challenges such as PRES and unusual manifestations of GVHD such as immune cytopenia. Early interventions to optimize supportive care and measures to reduce GVHD are required to ensure survival rates of over 90%.

20 August 2018 in Indian Pediatrics
Verified
Journal Article
Closed access
PDF file
RURamya Uppuluri
Ramya Uppuluri
DJDhaarani Jayaraman
Dhaarani Jayaraman
MSMeena Sivasankaran
Meena Sivasankaran
SPShivani Patel
Shivani Patel
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
RRRevathi Raj
Revathi Raj

25 November 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
KRKesavan Melarcode Ramanan
Kesavan Melarcode Ramanan
RURamya Uppuluri
Ramya Uppuluri
NRNikila Ravichandran
Nikila Ravichandran
SPShivani Patel
Shivani Patel
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
RRRevathi Raj
Revathi Raj

1 December 2020 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
RURamya Uppuluri
Ramya Uppuluri
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
KRKesavan Melarcode Ramanan
Kesavan Melarcode Ramanan
SMSatishkumar Meena
Satishkumar Meena
HVHarika Varla
Harika Varla
RRRevathi Raj
Revathi Raj
Fanconi anemia is the most common inherited bone marrow failure syndrome, and hematopoietic stem cell transplantation (HSCT) is the only curative option. Post-transplant cyclophosphamide (PTCy) is challenging in this group of children, given their increased sensitivity to chemotherapy. We performed a retrospective analysis of the data on children diagnosed with Fanconi anemia who underwent a haploidentical HSCT with PTCy from January 2014 to December 2019. Nineteen children (male/female, 0.75:1) underwent 21 haplo-HSCTs with PTCy. Fludarabine, low-dose cyclophosphamide, and 200 centi-gray total body irradiation were included in the conditioning regimen with 25 mg/kg PTCy on days +3 and +4. Haplo-graft was from a sibling in 38% and father in 57% of transplants. The source of stem cells was peripheral blood stem cells in 81% and bone marrow in 19% of transplants, with a median CD34 dose of 5.0 × 106/kg. We documented engraftment in 84% and primary graft failure in 10% of transplants. N-acetylcysteine (NAC) was infused concomitantly during cyclophosphamide in 13 children. Grade 2 and 3 mucositis was lower among those who received NAC as compared to those who did not (30% and 15% versus 33% and 50%), while transaminitis was higher among those who did not receive the infusion. The incidence of acute graft-versus-host disease (GVHD) was 68%, and 81% of these were steroid responsive (grade I/II). We documented chronic GVHD in 25% children, predominantly involving the skin and mouth, which responded to low-dose steroids and ruxolitinib. Serum ferritin was monitored twice weekly as a surrogate marker for cytokine release syndrome due to nonavailability of IL-6 levels. A 1- or 2-log increase in the titers of ferritin associated with clinical features guided the early addition of steroids in the periengraftment period. The mean survival was found to be less among those with high serum ferritin (>10,000 ng/dL) in the periengraftment period as compared to those with ferritin <10,000 ng/dL (mean survival of 25 ± 10 months versus 50 ± 6 months, respectively). The overall survival in our cohort was 68.4%, with a mean survival time of 41.5 months (95% confidence interval, 29.3 to 53.8 months), with a statistically significant correlation between inferior outcome and having received over 15 transfusions before HSCT (P = .01). PTCy can be considered a viable option in children with Fanconi anemia, particularly in resource-limited settings given the high costs of HSCTs. Focused interventions in this subset of children help improve survival outcomes. Early identification of cytokine release syndrome and risk-adapted steroid therapy during engraftment helps prevent mortality. The concomitant use of NAC during cyclophosphamide infusion helps reduce oxygen free radical related tissue damage and regimen-related toxicity.

27 October 2020 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
NRNikila Ravichandran
Nikila Ravichandran
KRKesavan Melarcode Ramanan
Kesavan Melarcode Ramanan
SMSatish Kumar Meena
Satish Kumar Meena
HVHarika Varla
Harika Varla
RRRevathi Raj
Revathi Raj